SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

$BYTE.X is trending due to its association as Grok AI's dog and a potential connection to Elon Musk, fueling speculation within the AI meme coin sector. Community members are actively discussing its strong holder base, zero transaction taxes, and potential for significant growth during the anticipated altseason. The focus is on its potential as a community-owned gem on Ethereum.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending, and the community is actively engaging with the classic 'What's UpDog?' joke, driving its visibility. Built on Solana and listed on Jupiter Strict List, this joke-meta coin has maintained a dedicated community for over a year, focusing on community and memetic appeal.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the community discusses its potential to break key resistance levels and make a parabolic move, with some anticipating a squeeze on short positions. Optimism is fueled by observations of coins leaving exchanges and a sense that the market is shifting away from altcoins. Broader conversations touch on the impact of potential government shutdowns and historical performance trends.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

$CAW.X is trending as the community rallies around the 'crow with knife' meme, calling it the only option for generational wealth. Discussions highlight its strong community, deflationary mechanisms, and expansion across multiple chains. The focus remains on community engagement and the potential for significant growth within the meme coin sector.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MLTX is trending due to positive Phase 2 trial results for its hidradenitis suppurativa treatment, sonelokimab, generating significant community excitement. Discussions revolve around the drug's potential efficacy and a possible acquisition, with some speculating on buyout prices and comparing it to competitor data. The stock's high short interest and potential for a squeeze are also being actively discussed.

Pump.fun

$PUMP.X is trending as traders discuss potential for significant gains and monitor entry points, while some caution about corrections. The community highlights the platform's buyback program and the organic growth of associated tokens like $WAGMI.X, emphasizing the potential for "tokenized positivity" within the Solana ecosystem.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is trending as the community discusses its potential breakout and accumulation at current prices, with some anticipating a significant upward move. Bullish sentiment seems to be fueled by discussions around altcoin season and NEAR's position in the AI crypto space. There's also chatter about potential partnerships and advancements in NEAR's underlying technology contributing to the positive outlook.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry ($BB.TSX) is trending amid renewed investor optimism, fueled by strong partnerships and expectations for upcoming earnings. The community is closely watching for continued growth in QNX, a key software platform, and potential revenue from existing royalty backlog.  Many believe a significant breakout is imminent, driven by the company's shift towards cybersecurity and IoT.

Doodles is a next-generation entertainment company focused on immersive storytelling through the creation and distribution of live and digital experiences, original content, and lifestyle products.  Doodles mission is to define the standard for immersive storytelling and color the world with joy.

Doodle Inu

Doodle Inu ($DOOD.X) is trending as the community rallies around a potential breakout, particularly a push towards the 50 mark.  Enthusiasm is fueled by recent price appreciation and comparisons to other meme coins, with some speculating on future collaborations and airdrops.  However, some users are expressing concerns about bot activity and potential pullbacks.

Meet Pandu — your AI friend who’s always by your side. Talk with him in real time through text or voice, share your thoughts, ask questions, or just enjoy a casual conversation. Whether you’re looking for advice, company, or simply someone to listen, Pandu is here as a true companion you can connect with anytime.  Pandu unites real-time conversation, creative generation, and future-ready AI systems — all powered by next-gen technology.

Pandu Pandas

Pandu Pandas ($PANDU.X) is trending, with community members highlighting its recent listing on MEXC and drawing comparisons to other successful meme coins. Bullish sentiment is fueled by perceived solid fundamentals and the project's NFT ranking, with many urging others to research the token. Some users are also discussing preferred wallets for holding $PANDU.X.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Top Analyst Reports for Microsoft, Amazon.com & Philip Morris

Microsoft, Amazon.com and Philip Morris headline fresh analyst reports highlighting AI, cloud, and smoke-free growth momentum.

UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals

United Therapeutics hit a record high after its Tyvaso study in idiopathic pulmonary fibrosis met key goals and showed broad patient benefits.

Electromed traded higher after hours on Tuesday as management highlighted hospital market share gains from a “distracted rival”, a strategy they credited with contributing to the company’s 11th straight quarter of year-over-year revenue and profit growth.The stock closed up 2.3% at $20.66 on Tuesday and jumped another 12.6% after hours following its earnings release.The maker of the SmartVest airway clearance system reported record fourth-quarter revenue of $17.4 million, up 17% from last year, as profit rose 21% to $2.2 million, or $0.25 a share.&nbsp;On the earnings call, Electromed detailed growth drivers beyond the headline numbers. Executives said hospitals are proving to be a “gateway” channel as patients introduced to SmartVest in care settings are often discharged with prescriptions for home use.&nbsp;CEO Jim Cunniff added that a major competitor with an “older product” is internally distracted, creating opportunities for market share growth.The company also highlighted strong e-prescribe adoption, with 38% of orders now submitted digitally, resulting in a halving of&nbsp;fulfillment times. A new Salesforce-based CRM integrating sales and reimbursement teams has also been rolled out, earning positive early feedback.&nbsp;Productivity gains continue, with sales&nbsp;representatives averaging $1.06 million each in annual revenue, up from $850,000 three years ago. Expansion to 61 territories is planned for FY26.Electromed is also benefiting from greater awareness of bronchiectasis after Insmed’s new drug launch, which executives said is raising disease visibility without competing on airway clearance.&nbsp;Earlier this month, the U.S. Food and Drug Administration (FDA)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/insmed-announces-fda-approval-for-drug-to-treat-chronic-lung-disease/chrxJPSRdJk">approved Insmed’s Brinsupri</a>, an oral once-daily treatment, as the first and only FDA-approved therapy for non-cystic fibrosis bronchiectasis (NCFB).&nbsp;The drug is cleared for use in adults and children aged 12 and older.&nbsp;Electromed noted over 31,000 visits to its bronchiectasis campaign site and cited registry data showing 58% of patients meeting criteria for HFCWO therapy remain untreated, a gap it sees as a major market opportunity.On Stocktwits, retail sentiment for Electromed was ‘bullish’ amid ‘high’ message volume.<a href="https://stocktwits.com/symbol/ELMD">Electromed’s stock</a> has declined over 30% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Electromed’s stock (ELMD) has declined over 30% so far in 2025. (Photo credit: Getty Images)

Why Electromed Stock Jumped 12% After-Hours: A Rival’s Weakness And A New Drug Tailwind

The after-hours surge came as management pointed to hospital market share gains from a distracted competitor and rising bronchiectasis awareness following Insmed’s FDA-approved drug launch.

Equity

H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the shares after the firm’s Brinsupri got approved as a treatment for non-cystic fibrosis bronchiectasis (NCFB).The new price target of $240 represents a near 97% upside to INSM’s closing price on Tuesday.H.C. Wainwright sees Insmed as "poised to join the ranks" of Roche's (RHHBY) Genentech and Pfizer's (PFE) Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy, said the analyst. Wainwright believes that Brinsupri and its next-generation versions will be able to treat a broad range of neutrophil-mediated diseases.Given the approval and potential for a "pipeline-in-a-pill", the firm now includes chronic rhinosinusitis without nasal polyps (CRSsNP) and hidradenitis suppurativa (HS) indications in its valuation, assuming a launch by 2027 for CRSsNP and a launch by 2028 for HS.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/INSM">Insmed</a> trended in the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1252/120;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_13_at_1_21_34_PM_png_eb547ea1d1.webp" alt="INSM's Sentiment Meter and Message Volume as of 1:21 p.m. ET on Aug. 13, 2025 | Source: Stocktwits" width="1252" height="120"><figcaption>INSM's Sentiment Meter and Message Volume as of 1:21 p.m. ET on Aug. 13, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the shares to hit $150 by the end of the week.<stembedurl>https://stocktwits.com/king9885/message/624942721</stembedurl>Brinsupri, an oral, once-daily treatment, is now the first and only FDA-approved treatment for NCFB. It was <a href="https://stocktwits.com/news-articles/markets/equity/insmed-announces-fda-approval-for-drug-to-treat-chronic-lung-disease/chrxJPSRdJk">approved</a> on Tuesday for adults as well as children aged 12 years and older.Bronchiectasis is a serious, chronic lung disease that causes airways to permanently widen due to a cycle of infection, inflammation, and lung tissue damage. Symptoms include chronic cough, excessive sputum production, shortness of breath, and repeated respiratory infections, which can worsen the underlying condition. A hallmark of bronchiectasis is frequent exacerbations, or flares, when symptoms worsen.In a late-stage study, patients taking Brinsupri 10 mg or 25 mg had a 21.1% and 19.4% reduction in the annual rate of exacerbations, respectively, as compared to placebo. Both dosage strengths of Brinsupri also significantly prolonged the time to first exacerbation.INSM stock is up by 76% this year and by 59% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/reshape-lifesciences-stock-rockets/chrC0AtRd9N">ReShape Lifesciences Stock Rocketed 61% Today – Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Insmed Incorporated logo is seen displayed on a smartphone. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week

The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy.

Insmed shares got a wave of bullish calls Tuesday after U.S. regulators cleared its new drug Brinsupri, the first treatment approved for non-cystic fibrosis bronchiectasis (NCFB).&nbsp;The stock jumped 8.1% on Tuesday, closing at&nbsp;its highest level in nearly 25 years before slipping 0.6% in after-hours trading.The once-a-day oral medicine is approved for adults and children 12 and older, offering a new option for patients with a condition that has had no dedicated therapies until now.NCFB is a long-term lung disease that causes permanent widening of the airways, driven by a cycle of infection, inflammation, and tissue damage. Symptoms include chronic cough,&nbsp;excessive mucus production, shortness of breath, and frequent infections, which can lead to exacerbations.&nbsp;In the U.S., Europe, and Japan, Insmed estimates the addressed patient population at 500,000, 600,000, and 150,000 diagnosed patients, respectively.Approval was based on late- and mid-stage data, in which Brinsupri reduced annual flare-ups by 21.1% at the 10 mg dose and 19.4% at the 25 mg dose compared to placebo. Both doses also delayed the time to&nbsp;the first flare.&nbsp;Applications have already been filed in Europe and the U.K., with a submission in Japan planned for 2025. If cleared overseas, Insmed expects to launch in those markets starting in 2026.Wells Fargo’s Tiago Fauth raised his price target to $140 from $130 and maintained an ‘Overweight’ rating, noting that approval had been expected, but the higher-end pricing could help the drug reach a market worth over $5 billion.&nbsp;RBC Capital’s team raised its target to $138 from $120 and called the label “a best-case scenario,” noting that both doses were approved without major warnings, key trial endpoints were met, and there was no exacerbation cutoff. They see the U.S. market at $3.8 billion and the global opportunity topping $6 billion.Meanwhile, Bank of America stuck with its $121 target and ‘Buy’ rating, saying the label contained no surprises. While approval is a major milestone, the bank said the bigger question now is whether Insmed can deliver on its own $5 billion peak sales projection.On Stocktwits, retail sentiment for Insmed was ‘extremely bullish’ amid a 340% surge in 24-hour message volume.One user remarked that Insmed looked like a strong long-term hold, predicting a major growth phase ahead and noting that many patients have no alternatives. They added that with minimal side effects or warnings, the drug could more easily be used for other conditions.<stembedurl>https://stocktwits.com/InvestorWisdom/message/624897660</stembedurl>Another user called the FDA label “a thing of beauty,” saying it effectively doubled the addressable market for non-cystic fibrosis bronchiectasis.&nbsp;They described the decision as a “grand slam” for the company, suggesting it could take off further if upcoming BiRCH trial results confirm Brinsupri’s broader potential.<stembedurl>https://stocktwits.com/JoeB07/message/624878902</stembedurl>Insmed’s stock has risen 76.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Insmed Stock Closes At Nearly 25-Year High As Analysts Get Bullish On FDA Nod For Lung Disease Drug: Retail Traders Ecstatic

Insmed shares surged after U.S. regulators approved Brinsupri, the first treatment for non-cystic fibrosis bronchiectasis.

Insmed (INSM) said on Tuesday that the U.S. Food and Drug Administration (FDA) has approved its Brinsupri drug in the treatment of non-cystic fibrosis bronchiectasis (NCFB).Brinsupri, an oral, once-daily treatment, is now the first and only FDA-approved treatment for NCFB, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.insmed.com/2025-08-12-FDA-Approves-BRINSUPRI-TM-brensocatib-as-the-First-and-Only-Treatment-for-Non-Cystic-Fibrosis-Bronchiectasis,-a-Serious,-Chronic-Lung-Disease">said</a>. It is approved in adults as well as children aged 12 years and older.<a href="https://stocktwits.com/symbol/INSM">INSM</a> stock jumped 4% on Tuesday afternoon following the news. On Stocktwits, retail sentiment around the stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.Bronchiectasis is a serious, chronic lung disease that causes airways to permanently widen due to a cycle of infection, inflammation, and lung tissue damage. Symptoms include chronic cough, excessive sputum production, shortness of breath, and repeated respiratory infections, which can worsen the underlying condition. A hallmark of bronchiectasis is frequent exacerbations, or flares, when symptoms worsen.Most cases of Bronchiectasis in adults are non-cystic fibrosis bronchiectasis, Insmed noted. According to the company, about 500,000 patients in the U.S., 600,000 patients in France, Germany, Italy, Spain, and the U.K., and 150,000 patients in Japan have been diagnosed with NCFB.Brinsupri’s FDA approval is based on data from a late-stage and mid-stage trial. In the late-stage study, patients taking Brinsupri 10 mg or 25 mg had a 21.1% and 19.4% reduction in the annual rate of exacerbations, respectively, as compared to placebo. Both dosage strengths of Brinsupri also significantly prolonged the time to first exacerbation.Insmed said that its applications for the drug with the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have been accepted, and the company plans to file for approval in Japan in 2025. Commercial launches are anticipated in 2026, pending approval in each territory, it added.INSM stock is up by 70% this year and by about 59% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-in-spotlight-as-fda-reportedly-mulls-withdrawing-authorization-for-covid-vaccine-for-kids-under-5/chrxIiKRdJL">Pfizer In Spotlight As FDA Reportedly Mulls Withdrawing Authorization For COVID-19 Vaccine For Kids Under 5: Retail Says Stock Is Undervalued</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Insmed Announces FDA Approval For Drug To Treat Chronic Lung Disease

Brinsupri, an oral, once-daily treatment, is now the first and only FDA-approved treatment for non-cystic fibrosis bronchiectasis, the company said.

Don't Overlook Insmed (INSM) International Revenue Trends While Assessing the Stock

Explore Insmed's (INSM) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Insmed (INSM) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Insmed (INSM) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Insmed (INSM) Reports Q2 Loss, Beats Revenue Estimates

Insmed (INSM) delivered earnings and revenue surprises of -30.77% and +3.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Fortrea Holdings Inc. (FTRE) Beats Q2 Earnings and Revenue Estimates

Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of +216.67% and +12.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Insmed Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

INSM
Insmed Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest INSM News

INSM Insmed Inc